Heron Therapeutics, Inc. filed a Form 8-K on November 9, 2026, disclosing that on November 8, 2026, it entered into an Asset Purchase Agreement with CorMedix Inc. to sell substantially all of its assets for a combination of cash, stock, royalties, and potential earn-out payments.
Key Highlights
- Cash consideration: CorMedix has agreed to pay Heron Therapeutics $145.0 million in cash, subject to certain adjustments for closing cash and net working capital, with $2.0 million deposited into escrow with Citibank, N.A. at closing.
- Stock consideration: CorMedix will issue 14,583,333 shares of its common stock (par value $0.001 per share) to Heron Therapeutics as part of the transaction.
- Royalties: CorMedix will pay 5.0% royalties on aggregate annual net sales of CINVANTI, SUSTOL, and products covered by a multi-product Development and License Agreement exceeding $25.0 million in each of calendar years 2027, 2028, and 2029, if and when payable.
- Earn-out payments: Heron may receive $25.0 million if ZYNRELEF net sales for calendar year 2028 reach $65.0 million, and an additional $30.0 million if such sales reach $95.0 million, payable in cash, CorMedix stock, or a combination.
- Termination fee: Heron Therapeutics would owe CorMedix a $4.0 million termination fee if it terminates the agreement to pursue a superior proposal.
- No liquidation planned: According to the filing, the company does not intend to liquidate following the closing and the board intends to evaluate strategic transactions and opportunities for the use of proceeds.
- Post-closing restrictions: Heron agreed to a five-year covenant not to compete in certain chemotherapy-induced nausea, post-operative nausea, and post-operative pain product areas, and a three-year non-solicitation covenant covering employees transferring to CorMedix.
Heron Therapeutics and CorMedix Asset Sale: Key Terms and Board Considerations
According to the filing, Heron Therapeutics (NASDAQ:HRTX) entered the Asset Purchase Agreement with CorMedix Inc. on November 8, 2026. Under the agreement, Heron agreed to sell substantially all of its assets to CorMedix, excluding certain assets the company will retain, including its federal income tax net operating loss carryforwards, shares of CorMedix common stock issued in the transaction, rights to future royalties and earn-out payments, and cash on hand. The filing states that CorMedix's obligation to close is not subject to any financing conditions.
The filing discloses that Heron intends to use a portion of the net proceeds to repay all amounts outstanding under its Working Capital Facility Agreement, dated August 9, 2023, with Hercules Capital, Inc. serving as administrative agent and collateral agent. Beyond that repayment, the board stated it intends to actively evaluate strategic opportunities, which the filing describes as potentially including "acquiring or investing in additional businesses or assets, which may or may not be pharmaceutical or biotechnology businesses or assets," encompassing products, product candidates, milestone payments, royalty streams, and other transactions. The filing notes it is "currently uncertain" what businesses or assets the company may acquire or invest in following the closing.
The Purchase Agreement includes customary non-solicitation provisions restricting Heron from soliciting or entering into discussions regarding competing proposals, subject to certain exceptions. The board retains the ability, subject to conditions, to change its recommendation in favor of the agreement if it determines in good faith, after consulting with its financial advisor and outside legal counsel, that a competing proposal constitutes a superior proposal and that failing to change its recommendation would be "reasonably likely to be inconsistent with the directors' fiduciary duties under applicable law." Post-closing adjustments to the cash consideration may not exceed $10.0 million in either direction, the filing states. The representations and warranties of the parties do not survive the closing, and the filing states Heron "will have no liability following the Closing for any breach of its representations and warranties, other than in the case of fraud."
What Was Disclosed
Heron Therapeutics filed an 8-K reporting entry into an Asset Purchase Agreement with CorMedix Inc. on November 8, 2026, covering the proposed sale of substantially all Heron assets for $145.0 million in cash, 14,583,333 CorMedix shares, royalties, and potential earn-out payments totaling up to $55.0 million.



Please wait processing your request...